Shots:

• In the HIBISCUS I induction study- in patients without prior anti-TNF treatment- etrolizumab met its 1EPs while in HIBISCUS II study in the same kind of people- it did not meet its 1EPs. In the HICKORY study- in patients with prior anti-TNF treatment- therapy met its 1EPs at induction but not at maintenance
• In the LAUREL maintenance study in people without prior anti-TNF treatment- etrolizumab failed to meet its 1EPs while the safety profile of therapy was consistent with previous studies and no major safety issues were reported till date in the four P-III studies
• The therapy is currently being evaluated as an induction/maintenance treatment in people with mod. to sev. active CD with/out prior anti-TNF treatment in a global P-III study (BERGAMOT) and OLE and safety monitoring study (JUNIPER)- involving 1-100+ people with CD. In addition- Roche is studying other therapies in IBD and is committed to further understanding this disease

­ Ref: Roche | Image: Roche